Back to results
US 12,465,029 B2Granted
Genetically modified cells, tissues, and organs for treating disease
AssigneeRegents of the University of Minnesota
InventorsBernhard J. Hering, Christopher Burlak
Life of this patent
Estimating the term…
Abstract
Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.
Claims20
A tolerizing regimen for administration to a human subject, the tolerizing regimen comprising:
- a tolerizing cell vaccine that comprises apoptotic leukocytes that comprise leukocytes chemically cross-linked with a crosslinking agent, wherein the leukocytes are human leukocytes or leukocytes from a member of a Laurasiatheria superorder;
- an mTOR inhibitor;
- a tumor necrosis factor alpha inhibitor;
- an interleukin 6 inhibitor;
- and
- an anti-CD40 agent or an anti-CD-154 agent;
- wherein said tolerizing regimen is formulated as one or more compositions that upon administration to a human subject result in a reduced T-cell activation in the human subject as compared to the T-cell activation in said subject absent said administration.
4 more elements
A method of tolerizing a human subject to an antigen or an antigenic epitope, the method comprising:
- administering to the human subject an effective amount of a tolerizing regimen comprising:
- a tolerizing cell vaccine that comprises antigen-coupled cells or epitope-coupled cells that comprise leukocytes chemically cross-linked with a crosslinking agent and said antigen or antigenic epitope, wherein the leukocytes are human leukocytes or leukocytes from a member of the Laurasiatheria superorder;
- an mTOR inhibitor;
- a tumor necrosis factor alpha inhibitor;
- an interleukin 6 inhibitor;
- and
- an anti-CD40 agent or an anti-CD-154 agent;
- wherein said tolerizing regimen is formulated as one or more compositions that upon administration to said human subject result in a reduced activation of T cells specific for the antigen or antigenic epitope in the human subject as compared to the activation of said T cells in said human subject absent said administration.
5 more elements
Dependencies are inferred from the claim text.